Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Harrow Health ( (HROW) ).
On February 2, 2026, Harrow reaffirmed its 2025 full-year revenue guidance of $270–$280 million, citing another year of strong growth in 2025 and outlining an aggressive commercial expansion centred on its key ophthalmic brands VEVYE, IHEEZO and TRIESENCE. The company is doubling the VEVYE sales force to about 100 U.S. territories following favourable pharmacy benefit coverage that began on January 1, 2026, broadening IHEEZO’s reach into an estimated 2.5 million-procedure office-based market, and doubling the surgical sales force behind TRIESENCE on the back of robust clinical feedback and rising demand. Harrow has launched its OneHarrow initiative to consolidate all products, including compounded formulations, under a single Harrow-branded commercial organization to improve alignment, efficiency and market impact, while promoting Patrick W. Sullivan—who joined in August 2025—to Chief Commercial Officer to strengthen the commercial foundation and drive progress toward its 2027 financial goals. On the development front, Harrow reported that integration of Melt Pharmaceuticals is complete and that required ancillary studies for MELT-300 are underway, keeping the New Drug Application filing timeline on track for the first half of 2027, while MELT-210 also advances toward filing. The company’s ImprimisRx division settled all pending regulatory matters with the California Board of Pharmacy, agreed to an administrative fine of about $157,000 and voluntarily exited the California compounding market effective February 1, 2026, a move Harrow described as not financially material and driven by the state’s increasingly costly and unpredictable regulatory environment; Harrow will continue to serve California with its branded products while focusing ImprimisRx on the other 49 states.
The most recent analyst rating on (HROW) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is most constrained by financial risk factors—high leverage and notably weak/free cash flow trends—despite solid revenue growth and strong gross margins. Technicals are supportive but look overextended (RSI/Stoch elevated). Earnings call commentary is constructive on growth, coverage wins, and product pipeline, but execution risks (TRIESENCE softness and ImprimisRx issues) temper the upside; valuation support is limited given the negative P/E and no dividend yield.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow (Nasdaq: HROW) is a North America-focused provider of ophthalmic disease management solutions, offering a broad portfolio of branded and compounded products that treat conditions affecting both the front and back of the eye, including dry eye disease, neovascular age-related macular degeneration, cataracts, refractive errors, glaucoma and various ocular surface and retinal disorders. The company emphasizes delivering safe, effective, accessible and affordable medications aimed at improving patient compliance and clinical outcomes, and is evolving into a national, broad-based ophthalmic therapeutics platform under a unified Harrow brand.
Average Trading Volume: 613,098
Technical Sentiment Signal: Buy
Current Market Cap: $1.52B
For a thorough assessment of HROW stock, go to TipRanks’ Stock Analysis page.